Phase III trial of Regeneron and Bayer's Eylea initiated in China

29 November 2011

USA-based Regeneron Pharmaceuticals (Nasdaq: REGN) and German partner Bayer (BAY: DE) have initiated a Phase II clinical trial evaluating the efficacy and safety of Eylea (aflibercept) Injection in the neovascular form of age-related macular degeneration (wet AMD) in China. The news saw Regeneron’s shares jump 6.9% to $57.50 in morning trading yesterday.

The new trial, named SIGHT, will include around 300 patients and will be the largest retinal trial conducted in China. SIGHT is being led by Bayer. The news comes just a week after the US Food and Drug Administration approved Eylea, which is also filed with regulatory agencies in Europe and Japan (The Pharma Letter November 1 and June 30). Bayer has rights to market the product, which has been billed as having a $2 billion global sales potential by 2018, outside the USA.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK